Immune System Key Ltd.
    • Home
    • News & Events
    • Science And R&D
      • Nerofe Pipeline
      • Technology
      • Nerofe Mode of Action
      • Phase I Results
      • First Success Story
    • Company Description
      • Team
    • Contact Us
    Immune System Key Ltd.
    • Home
    • News & Events
    • Science And R&D
      • Nerofe Pipeline
      • Technology
      • Nerofe Mode of Action
      • Phase I Results
      • First Success Story
    • Company Description
      • Team
    • Contact Us

    Harvard-Logo

    • Home
    • Harvard-Logo

    Harvard-Logo

    27/10/2019

    Joel Ohana2019-10-27T17:33:05+02:0027 Oct|

    Related Posts

    • Dr. Devary: Transforming “Cold Tumors” into “Hot Tumors”: Nerofe and DOX Synergy against KRAS Mutations

      26/10/2023
    • Second FDA approved clinical trial in patients with pancreatic cancer and metastatic colorectal

      18/12/2022

      ISK is excited to report the official opening of its second FDA approved clinical trial in the US in patients with pancreatic cancer and metastatic colorectal cancer at Georgetown University in Washington, D.C.

    • ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC

      23/10/2022

      ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC

    • Georgetown University at Washington DC has signed a contract with ISK to run a clinical trial with patients with mtKRAS tumors

      17/02/2022

      The prestigious medical center Georgetown University at Washington DC has sign a contract with ISK to run a clinical trial with patients with mtKRAS pancreas and colon cancers.

    • PHASE 1B/2A Clinical trial started

      13/04/2021
    • Permalink Gallery

      Dr. Devary: Transforming “Cold Tumors” into “Hot Tumors”: Nerofe and DOX Synergy against KRAS Mutations

    • Permalink Gallery

      Second FDA approved clinical trial in patients with pancreatic cancer and metastatic colorectal

    • Permalink Gallery

      ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC

    • Permalink Gallery

      Georgetown University at Washington DC has signed a contract with ISK to run a clinical trial with patients with mtKRAS tumors

    • Usylvester
      Permalink Gallery

      PHASE 1B/2A Clinical trial started

    Recent Posts

    • ISK Ltd is a resident company of Johnson & Johnson Innovation – JLABS
    • Advancing Cancer Treatment with Enhanced Nerofe
    • Dr. Devary: Transforming “Cold Tumors” into “Hot Tumors”: Nerofe and DOX Synergy against KRAS Mutations
    • Second FDA approved clinical trial in patients with pancreatic cancer and metastatic colorectal
    • IRB approval to open the trial in Georgetown University for the treatment of mtKRAS tumors from GI track

    Tags

    AML AML drug cancer Clinical Trial human trial MDS Nerofe phase II research Treatment Video

    Categories

    • News
    • About
    • News & Events
    • Contact Us
    • Disclaimer
    Immune System Key (ISK) Ltd. Hava'ad Haleumi 21, Jerusalem 91160, Israel Tel: +972-50-2597031/2
    logo
    Copyright © 2015 ISK Ltd.